The International Society for Cell and Gene Therapy (ISCGT) of Cancer annual meeting was held from September 2 through September 4, 2009, in Cork, Ireland (www.iscgt2009.com). The conference was held in conjunction with the Irish Society for Gene and Cell Therapy third annual meeting, and brought together scientists and clinicians from around the world in a country developing its knowledge economy. Next year's ISCGT meeting will be held in Doha, the capital of Qatar (www.iscgt.net), from September 27 through September 29, 2010.
Get full access to this article
View all access options for this article.
References
1.
AloysiusM.M., McKechnieA.J., RobinsR.A., VermaC., EreminJ.M., FarzanehF., HabibN.A., BhallaJ., HardwickN.R., SatthapornS., SreenivasanT., El-SheemyM., EreminO.2009. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J. Transl. Med., 7:18.
2.
BoulterJ.M., GlickM., TodorovP.T., BastonE., SamiM., RizkallahP., JakobsenB.K.2003. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng., 16:707–711.
3.
CollinsC.G., TangneyM., LarkinJ.O., CaseyG., WhelanM.C., CashmanJ., MurphyJ., SodenD., VejdaS., McKennaS., KielyB., CollinsJ.K., BarrettJ., AaronsS., O'SullivanG.C.2006. Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors. Cancer Gene Ther., 13:1061–1071.
4.
CroweO.M., DysonS.J., WrightI.M., SchrammeM.C., SmithR.K.2004. Treatment of chronic or recurrent proximal suspensory desmitis using radial pressure wave therapy in the horse. Equine Vet. J., 36:313–316.
5.
CunninghamD., AllumW.H., StenningS.P., ThompsonJ.N., Van De VeldeC.J., NicolsonM., ScarffeJ.H., LoftsF.J., FalkS.J., IvesonT.J., SmithD.B., LangleyR.E., VermaM., WeedenS., ChuaY.J.MAGIC Trial Participants. 2006. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med., 355:11–20.
6.
DummerR., RochlitzC., VeluT., AcresB., LimacherJ.M., BleuzenP., LacosteG., SlosP., RomeroP., UrosevicM.2008. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol. Ther., 16:985–994.
7.
FarzanehF., HabibN., WaldenP.2004. Cancer gene therapy: New horizons in the East International Society for Cancer Gene Therapy, Singapore, 20–22 February 2004. Cancer Immunol. Immunother., 53:1052–1053.
8.
GuinnB.A., MulherkarR.2008. International progress in cancer gene therapy. Cancer Gene Ther., 15:765–775.
GuinnB.A., NorrisJ.S., FarzanehF., DeisserothA.B.2007. International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China. Cancer Gene Ther., 14:128–138.
11.
GutmanS., KesslerL.G.2006. The US Food and Drug Administration perspective on cancer biomarker development. Nat. Rev. Cancer, 6:565–571.
12.
HardwickN., ChanL., IngramW., MuftiG., FarzanehF.2009. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol. Immunother., 2009Aug 27. [Epub ahead of print] PMID19711075.
13.
IngramW., KordastiS., ChanL., BarberL.D., TyeG.J., HardwickN., MuftiG.J., FarzanehF.2009. Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures. Cancer Immunol. Immunother., 58:1679–1690.
KostarelosK., MillerA.D.2005. Synthetic, self-assembly ABCD nanoparticles: A structural paradigm for viable synthetic non-viral vectors. Chem. Soc. Rev., 34:970–994.
16.
KurookaM., KanedaY.2007. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res., 67:227–236.
17.
LangF.F., BrunerJ.M., FullerG.N., AldapeK., PradosM.D., ChangS., BergerM.S., McDermottM.W., KunwarS.M., JunckL.R., ChandlerW., ZwiebelJ.A., KaplanR.S., YungW.K.2003. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J. Clin. Oncol., 21:2508–2518.
18.
LeenA.M., MyersG.D., SiliU., HulsM.H., WeissH., LeungK.S., CarrumG., KranceR.A., ChangC.C., MolldremJ.J., GeeA.P., BrennerM.K., HeslopH.E., RooneyC.M., BollardC.M.2006. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med., 12:1160–1166.
19.
LeenA.M., ChristinA., MyersG.D., LiuH., CruzC.R., HanleyP.J., Kennedy-NasserA.A., LeungK.S., GeeA.P., KranceR.A., BrennerM.K., HeslopH.E., RooneyC.M., BollardC.M.2009. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplant. Blood, 114:4283–4292.
20.
LiY., MoyseyR., MolloyP.E., VuidepotA.L., MahonT., BastonE., DunnS., LiddyN., JacobJ., JakobsenB.K., BoulterJ.M.2005. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol., 23:349–354.
21.
MeissnerA., MikkelsenT.S., GuH., WernigM., HannaJ., SivachenkoA., ZhangX., BernsteinB.E., NusbaumC., JaffeD.B., GnirkeA., JaenischR., LanderE.S.2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature, 454:766–770.
22.
MurphyJ., O'SullivanG.C., LeeG., MaddenM., ShanahanF., CollinsJ.K., TalbotI.C.2000. The inflammatory response within Dukes' B colorectal cancers: Implications for progression of micrometastases and patient survival. Am. J. Gastroenterol., 95:3607–3614.
23.
NorrisJ.S., BielawskaA., DayT., El-ZawahriA., ElojeimyS., HannunY., HolmanD., HyerM., LandonC., LoweS., DongJ.Y., McKillopJ., NorrisK., ObeidL., RubinchikS., TavassoliM., TomlinsonS., Voelkel-JohnsonC., LiuX.2006. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: A status report. Cancer Gene Ther., 13:1045–1051.
24.
PengZ.2005. Current status of Gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther., 16:1016–1027.
TrudelS., LiZ., DodgsonC., NanjiS., WanY., VoraliaM., HittM., GauldieJ., GrahamF.L., StewartA.K.2001. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma: A phase 1 study. Leukemia, 15:846–854.
31.
Van PijkerenJ., MorrisseyD., CroninM., RajendranS., O'SullivanG., GahanC., TangneyM.2009. A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum. Gene Ther.(in press).
32.
WellsJ.W., CowledC.J., FarzanehF., NobleA.2008. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J. Immunol., 181:3422–3431.
